12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

La Jolla Pharmaceutical preclinical data

In a mouse model of non-alcoholic steatohepatitis-hepatocellular carcinoma (NASH-HCC), thrice-weekly 25 mg/kg IV GCS-100 significantly reduced liver fibrosis, improved non-alcoholic...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >